Asian Tech Press (Nov 7) -- Clover Biopharmaceuticals Ltd. (2197.HK) announced Tuesday that it has completed the application to the Brazilian Health Regulatory Agency (Anvisa) for the marketing of its seasonal influenza vaccine.

Once approved, the Chinese biotech company will work further with local partners to commercialize the flu vaccine in Brazil, expanding the business into the southern hemisphere.

Clover noted that Brazil is an important vaccine market in terms of market strategy.

According to GlobalData, Brazil is the world's second-largest seasonal influenza vaccine market, and the total local market space is expected to exceed $1 billion over the next five years.

Founded in 2007 and listed on the Hong Kong Stock Exchange in November 2021, Clover is known for its adjuvanted protein-based COVID-19 vaccine candidate, SCB-2019.